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64 Population pharmacokinetics (PK) of tobramycin administered
thrice daily (TD) and once daily (OD) in children and adults with
CF
D.J. Touw1, A.J. Knox2, A. Smyth3. 1Apotheek Haagse Ziekenhuizen, Den
Haag, Netherlands; 2Centre for Respiratory Research, Nottingham City Hospital,
Nottingham, United Kingdom; 3Division of Child Health, University of Nottingham,
Nottingham, United Kingdom
Background: The TOPIC study (a randomised clinical trial investigating efﬁcacy
and toxicity of OD versus TD tobramycin in children and adults with CF) has
demonstrated that OD 10mg/kg tobramycin is at least equally effective and probably
less nephrotoxic than TD 3.3mg/kg. However, tobramycin PK have not been
compared previously in a large series children and adults with CF receiving OD or
TD tobramycin.
Methods: therapeutic drug monitoring data in children and adults who participated
in the TOPIC study were analysed retrospectively. Population PK models stratiﬁed
to treatment schedule were created and individual PK parameters were calculated.
Results: In paediatric patients, tobramycin volume of distribution per kg body
weight (V1) was greater with OD treatment compared to TD (0.401±0.092
versus 0.354±0.041 L/kg, p = 0.003). V1 decreased with increasing age (r2 = 0.3,
p< 0.001). Tobramycin elimination rate (Kel) was reduced in all patients receiving
OD compared to TD (children: 0.00197±0.00027 versus 0.00291±0.00041 h-1,
p< 0.001, adults: 0.00252±0.00008 versus 0.00322±0.00050 h-1, p< 0.001). The
OD group received tobramycin in the afternoon or early evening.
Conclusions: The higher V1 in children implies that a relative higher tobramycin
dose in these patients is needed for the same target peak serum concentration. The
reduced Kel in OD treatment may either be caused by circadian pharmacokinetic
behaviour of tobramycin or indicate early renal damage from the high tobramycin
doses not detected by biochemical measurements. However, results of the TOPIC
study suggest that OD administration of tobramycin may be less nephrotoxic.
65 Pharmacokinetics of Azithromycin during once weekly dosing in
cystic ﬁbrosis patients
E.B. Wilms1, H.G. Heijerman2, D.J. Touw1. 1Central Hospital Pharmacy, The
Hague, The Netherlands; 2Adult CF Centre, Haga Teaching Hospital, The Hague,
The Netherlands
Azithromycin (AZM) is widely used to suppress Pseudomonas infection. Optimal
dose however, is unknown. In this study we examined pharmacokinetics, systemic
exposure, sputum penetration and tolerability of Azithromycin (AZM) in CF patients
on a once weekly dosing scheme.
Eight adult CF patients using AZM 500mg per day were changed to a once weekly
dose of 1000mg for 3 months. Monthly sputum and blood samples were collected
and side effects were registered. From blood, plasma and polymorphonuclear
neutrophils were isolated. AZM was quantiﬁed in these samples. Pharmacokinetic
calculations were done with MwPharm.
Six patients reported no change in side-effects. Two patients experienced an increase
in transient nausia starting shortly after change to 1000mg AZM once weekly and
lasting 3−6 hours after intake. In sputum we found an average concentration of
26.6mg/l (sd = 15.6; min: 12mg/l, max: 62mg/l) at the dose of 500mg/day. At the
dose of 1000mg AZM once weekly we found an average concentration of 9.6mg/l
(sd = 7.1; min: 2.5mg/l, max: 20.9mg/l) in sputum collected between 144–168 hours
after dosing.
The cumulative weekly dose was reduced with a factor 3.5 (7×500mg vs
1×1000mg weekly). This led to a reduction in area under the curve (AUC±SD)
of 2.5±0.8 in plasma, 2.8±0.9 in blood, 2.3±1.1 in PMNN’s and to a reduction in
average sputum concentration of 3.0 (±1.5).
At 1000 mg once weekly reduced but still substantial concentrations were achieved
in PMNN’s and in sputum. Although not signiﬁcant, a tendency towards a less than
linear reduction of AUC was found. In order to calculate and propose an optimal
dosing scheme we need to establish a relation between exposure levels and clinical
efﬁcacy.
66 Safety of oral choramphenicol for pseudomonas aeruginosa
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Introduction: Oral ciproﬂoxacin is often used for Pseudomonas aeruginosa (PSA)
infections in cystic ﬁbrosis (CF) not requiring intravenous antibiotics. Concerns
about aplastic anaemia limit chloramphenicol use in many centres, but it is com-
monly used at the Royal Brompton Hospital (RBH). This study looks at sensitivities
of PSA to chloramphenicol and ciproﬂoxacin, and adverse haematological effects.
Study design:We carried out a retrospective review from RBH CF database (1985–
2004) together with analysis of patients notes.
Methods:
1. PSA sensitivities to ciproﬂoxacin and chloramphenicol were recorded from
sputum samples taken in late 2004
2. All blood dyscrasias in patients who had received chloramphenicol from 1985
to 2004 were reviewed.
Results:
1. 216 sputum samples from 216 patients grew PSA. Some were sensitive to only
one antibiotic, and there were some cross-sensitivities, but in total 35.46% were
sensitive to chloramphenicol and 54.25% to ciproﬂoxacin.
2. 648 patients had oral chloramphenicol and 755 oral ciproﬂoxacin from 1985–
2004. Multiple courses were often given, but usually no more frequent than
3 monthly with chloramphenicol. Over 20 years, 4 cases of blood dyscrasia
were recorded, none due to chloramphenicol, and all recovered.
Conclusion: A signiﬁcant proportion of PSA is sensitive to chloramphenicol
and in over 20 years there have been no documented cases of related aplastic
anaemia. Clinical improvements with choramphenicol comparable to ciproﬂoxacin
in outpatients were also recorded. Our data shows chloramphenicol is safe and
may be the oral antibiotic of choice in ciproﬂoxacin allergy or PSA resistant to
ciproﬂoxacin. Further evaluation of the efﬁcacy of the two antibiotics is indicated.
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Introduction: The impact of MRSA on CF-lung disease remains unclear. As
vancomycin (vanc) can only be administered iv and often induces allergic reactions,
oral linezolid (lnz) is a good alternative in respiratory exacerbations. Long-term
treatment is known to induce neurological adverse effects in some patients.
Methods: We retrospectively evaluated all our patients treated with lnz between
2001 and 2007 for neurological complaints.
Results: 36/300 (12%) patients followed in our units have been/are currently
colonized by MRSA. 11 patients received  1 courses of lnz <28 days [number
of courses (n): n = 1, 7/11 patients; n = 2, 2/11; n = 4, 1/11; n = 16, 1/11] and 3
received treatment >28 days (56 days, 172 days, 6 months). None of the patients
who received courses of <28 days developed neurological complaints whereas
2/3 patients receiving prolonged treatment did. A 18 yr-old man received lnz as a
last resort. 5 months into treatment he developed loss of sensibility and severe pain
in both feet. A peripheral sensitive neuropathy was diagnosed. Lnz was stopped.
Neurological signs regressed over 5 months. A 42-yr old woman received 56 days
lnz because of vanc allergy. She also received an antihistamine. She developed
painful peripheral neuropathy of the lower limbs with ataxia, and visual impairment
which persisted in spite of interruption of lnz.
Conclusion: Lnz is an alternative drug to treat MRSA-associated infections; how-
ever, it may induce persistent neurological adverse effects, especially if treatment
duration exceeds 28 days and in case of concomitant therapy with anticholinergic
agents. CF patients who are chronically exposed to multiple drugs may even have
a higher risk.
